Login to Your Account



Clinic Roundup


Wednesday, February 23, 2011
Santarus Inc., of San Diego, and Pharming Group NV, of Leiden, the Netherlands, announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb study evaluating the investigational drug Rhucin (recombinant human C1 inhibitor) for the treatment of acute attacks of angioedema in patients with hereditary angioedema.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription